New Findings from Yonsei University College of Medicine in the Area of Coagulation Modifiers Reported (The Use Pattern and Clinical Impact of New…

New Findings from Yonsei University College of Medicine in the Area of Coagulation Modifiers Reported (The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial ...)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Drugs and Therapies - Coagulation Modifiers. According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Despite the favorable efficacy of new antiplatelet agents demonstrated in randomized controlled trials, their clinical implications in Korea are unclear. The purpose of this study was to investigate trends in antiplatelet agent use for acute myocardial infarction (AMI) and their impact on 30-day clinical outcomes."

Our news journalists obtained a quote from the research from the Yonsei University College of Medicine, "AMI patients undergoing percutaneous coronary intervention between 2010 and 2015 were assessed using claim data from the Health Insurance Review and Assessment Service. The use of new antiplatelet agents has rapidly increased since 2013 and has been preferred over clopidogrel (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals) since 2015. Both prasugrel (Effient; Eli Lilly and Company) (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.31-0.67; p<0.001) and ticagrelor (Brilinta; AstraZeneca Pharmaceuticals LP) (OR, 0.84; 95% CI, 0.71-0.98; p=0.032) had an independent effect on lowering 30-day mortality in a weighted multivariable logistic regression model. However, new antiplatelet agents had no significant effect on other clinical outcomes including myocardial infarction, stroke, bleeding, and readmission within 30 days. The use of new antiplatelet agents is rapidly increasing, and they have been used more commonly than clopidogrel since 2015."

According to the news editors, the research concluded: "We demonstrated that new antiplatelet agents have a favorable effect on reducing 30-day mortality in AMI patients in Korea."

For more information on this research see: The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data. Korean Circulation Journal, 2017;(): (see also Drugs and Therapies - Coagulation Modifiers).

Our news journalists report that additional information may be obtained by contacting C. Kim, Division of Cardiology, Dept. of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea. Additional authors for this research include D.H. Shin, C.M. Ahn, J.S. Kim, B.K. Kim, Y.G. Ko, D. Choi, M.K. Hong, J. Park, H. Lee, Y.J. Choi, Y.S. Choi, S.K. Oh and Y. Jang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.4070/kcj.2017.0072. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antiplatelet Agents, Seoul, Prasugrel, South Korea, Heart Attack, Heart Disease, Health Insurance, Drugs and Therapies, Myocardial Ischemia, Coagulation Modifiers, Acute Myocardial Infarction, Heart Disorders and Diseases, Vascular Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC